Cargando…

Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model

Since ID93/GLA-SE was developed as a targeted BCG-prime booster vaccine, in the present study, we evaluated the protective efficacy of ID93/GLA-SE as a boost to a BCG-prime against the hypervirulent Mycobacterium tuberculosis (Mtb) K challenge to provide further information on the development and ap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwon, Kee Woong, Lee, Ara, Larsen, Sasha E., Baldwin, Susan L., Coler, Rhea N., Reed, Steven G., Cho, Sang-Nae, Ha, Sang-Jun, Shin, Sung Jae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820558/ https://www.ncbi.nlm.nih.gov/pubmed/31664157 http://dx.doi.org/10.1038/s41598-019-52146-0

Ejemplares similares

Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
por: Choi, Yu Hwa, et al.
Publicado: (2023)

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
por: Coler, Rhea N., et al.
Publicado: (2018)

Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults
por: Sagawa, Zachary K., et al.
Publicado: (2023)

Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine
por: Archer, Michelle C., et al.
Publicado: (2023)

Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations
por: Baldwin, Susan L., et al.
Publicado: (2022)

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model
por: Baldwin, Susan L., et al.
Publicado: (2021)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
por: Cauwelaert, Natasha Dubois, et al.
Publicado: (2016)

A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
por: Orr, Mark T., et al.
Publicado: (2014)

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE
por: Coler, Rhea N, et al.
Publicado: (2015)

Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
por: Larsen, Sasha E., et al.
Publicado: (2023)

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140
por: Arias, Mauricio A., et al.
Publicado: (2012)

Nanoscale Peptide Self-assemblies Boost BCG-primed Cellular Immunity Against Mycobacterium tuberculosis
por: Chesson, Charles B., et al.
Publicado: (2018)

Recombinant AhpC antigen from Mycobacterium bovis boosts BCG-primed immunity in mice
por: DÜZENLİ, Özgün Fırat, et al.
Publicado: (2021)

Development of the Sm14/GLA-SE Schistosomiasis Vaccine Candidate: An Open, Non-Placebo-Controlled, Standardized-Dose Immunization Phase Ib Clinical Trial Targeting Healthy Young Women
por: Santini-Oliveira, Marília, et al.
Publicado: (2022)

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design
por: Viegas, Edna O., et al.
Publicado: (2018)

The HyVac4 Subunit Vaccine Efficiently Boosts BCG-Primed Anti-Mycobacterial Protective Immunity
por: Billeskov, Rolf, et al.
Publicado: (2012)

Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against Mycobacterium kansasii
por: Komine-Aizawa, Shihoko, et al.
Publicado: (2021)

Repeated Aerosolized-Boosting with Gamma-Irradiated Mycobacterium bovis BCG Confers Improved Pulmonary Protection against the Hypervirulent Mycobacterium tuberculosis Strain HN878 in Mice
por: Cha, Seung Bin, et al.
Publicado: (2015)

The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases
por: Baldwin, Susan L., et al.
Publicado: (2019)

Prime Vaccination with Chitosan-Coated Phipps BCG and Boosting with CFP-PLGA against Tuberculosis in a Goat Model
por: Contreras-Magallanes, Yesenia Guadalupe, et al.
Publicado: (2021)

Self-adjuvanting nanovaccines boost lung-resident CD4(+) T cell immune responses in BCG-primed mice
por: Files, Megan A., et al.
Publicado: (2022)

Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant
por: Fernández, Laura, et al.
Publicado: (2021)

It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity
por: Larsen, Sasha E., et al.
Publicado: (2022)

Protection against highly pathogenic SIV by BCG-SIV recombinant priming and attenuated replicating vaccinia-SIV recombinant boosting
por: Zhang, X, et al.
Publicado: (2012)

Heterologous Boosting With Listeria-Based Recombinant Strains in BCG-Primed Mice Improved Protection Against Pulmonary Mycobacterial Infection
por: Liu, Si-Jing, et al.
Publicado: (2020)

The adjuvant GLA-AF enhances human intradermal vaccine responses
por: Carter, Darrick, et al.
Publicado: (2018)

Distant metastasis facilitated by BCG: spread of tumour cells injected in the BCG-primed site.
por: Ishibashi, T., et al.
Publicado: (1980)

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

Evolution of Matrix Gla and Bone Gla Protein Genes in Jawed Vertebrates
por: Leurs, Nicolas, et al.
Publicado: (2021)

E-DNA IM or ID delivery prime enhances antibody and T cell responses following recombinant gp120 env boost
por: Hutnick, NA, et al.
Publicado: (2012)

Intranasal Mucosal Boosting with an Adenovirus-Vectored Vaccine Markedly Enhances the Protection of BCG-Primed Guinea Pigs against Pulmonary Tuberculosis
por: Xing, Zhou, et al.
Publicado: (2009)

Protection against tuberculosis achieved by dissolving microneedle patches loaded with live Mycobacterium paragordonae in a BCG prime-boost strategy
por: Lee, Mi-Hyun, et al.
Publicado: (2023)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRβ clonotypes
por: Hill, Danika L., et al.
Publicado: (2019)

Airway delivery of both a BCG prime and adenoviral boost drives CD4 and CD8 T cells into the lung tissue parenchyma
por: Kaveh, Daryan A., et al.
Publicado: (2020)

Priming with a Recombinant Pantothenate Auxotroph of Mycobacterium bovis BCG and Boosting with MVA Elicits HIV-1 Gag Specific CD8(+) T Cells
por: Chapman, Rosamund, et al.
Publicado: (2012)

Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis
por: Nandakumar, Subhadra, et al.
Publicado: (2016)

Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
por: Gagelmann, Nico, et al.
Publicado: (2022)

GLA-AF, an Emulsion-Free Vaccine Adjuvant for Pandemic Influenza
por: Clegg, Christopher H., et al.
Publicado: (2014)

Abstract 1647: Quantification of functional antibody titers in a mouse model of SARS-CoV-2 infection
por: Hernandez, Dulce, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v7kgafm54smiqr21io8q3bkjc1